Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.
Craig A. Portell, MD, associate professor of medicine at University of Virginia, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology (SOHO) Annual Meeting.
According to Portell, as more is learned about Bruton’s tyrosine kinase (BTK) inhibitor resistance, it can be a challenge to know what to do afterwards. He adds that the chimeric antigen receptor (CAR) T-cell therapy space has been very helpful with this.
He also remains hopeful that more data on bispecific antibodies, covalent BTK inhibitors, venetoclax (Venclexta), etc., all of which are hard to know how to sequence, will continue to help address challenges in the field of relapsed/refractory mantle cell lymphoma.
Further, Portell offers some insights on what one can expect from this session at SOHO, as well as additional sessions that are of particular interest to him and colleagues.
Transcription:
0:09 | So, today I am going to be talking about sequencing therapies in relapsed mantle cell lymphoma. [We are] starting first with patients, whether they have been exposed to BTK inhibitors or not, and how that may impact the decision making, and then, after exposure to BTK inhibitors, how to fit CAR T-cell therapy in vs a non covalent BTK inhibitor, and [we will] talk about some special scenarios, particularly with p53-mutated relapse disease.
0:39 | [We will be] really going through the pathways of when a patient would relapse in various different scenarios. So, hopefully that will be informative and give some suggestions about how to manage patients in certain scenarios after progression with various different disease characteristics.
0:59 | [Overall], the lymphoma sessions, I think, in general, are going to be very well reviewed and thoughtful. So, I am looking forward to hearing what my colleagues have to say.
LITESPARK-005 Trial of Belzutifan Shows Survival Benefits in Advanced Clear Cell RCC
September 13th 2024A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear cell renal cell carcinoma.
Read More
In SCLC, Upfront BMS-986012 Plus Nivolumab/Chemotherapy Has Potential
September 13th 2024The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and chemotherapy alone.
Read More
Consolidation Durvalumab Shows Consistent Survival Improvements in LS-SCLC Subgroups
September 13th 2024The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.
Read More